Jim McCamant
1 Science good, investment insight bad
Disappointing. I guess this book is one example where the cover says it all; next time I see a book on Biotech investing, I want to see a dollar sign on the jacket.
Sure, I got the biotech bit, but where was the insight into investing. Nothing really hit me. I started reading the book not knowing how to invest in biotech; I ended the same way.
On a positive note, I did like the writing style.
2 Excellent Advice!
WOW! Such a dense topic, so carefully written. I am the wiser for this book. Thank you for presenting this so clearly.
3 Guide, but not an *Investors* guide
I picked up this book with two kinds of expectations. One that McCamant would give me the "lay of the land" of the Biotech space, the competing markets and the key companies. The other, that he would provide deep insight (a la Peter Lynch) on an investment method. On the first count, the book does a reasonable job. On the second count, it is very disappointing. Most of the investment rules are obvious and generic. The investment web links are outdated.
